Physician profile
Robin J Bernard
NPI 1326070012
$493.77
in general payments reported to CMS, 2019-2025
13 companies · $62.96 in 2025
The $62.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $23.28 · 2024: $141 · 2025: $62.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $142.03 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Emd Serono, INC. | $65.66 | 2019 | |
| Lundbeck LLC | $54.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $50.50 | 2019 | |
| Vanda Pharmaceuticals INC. | $39.40 | 2024 | Fanapt, Hetlioz |
| Hologic Sales and Service, LLC | $24.79 | 2024 | Thinprep 2000 Processor |
| Ironshore Pharmaceuticals INC. | $23.99 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $19.04 | 2024 | Invega Sustenna |
| Novo Nordisk INC | $18.43 | 2024 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $15.30 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $14.70 | 2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $14.04 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.